Diagnostic Utility of Fibrinogen Estimation by Clauss & PT Derived Method in an Oncology Setup

*Dr. Ritu Garg  
3rd year resident  
*Corresponding Author

Dr Jyoti Sawhney  
Associate professor

Dr. Dhaval Jetly  
Professor

Dr. M.J. Shah  
Professor & Head of the Department.

**ABSTRACT**

**Aim:** Fibrinogen assay is significant in area of thrombosis research since it is affected by various physiological and pathological conditions such inherited/acquired coagulopathies indicated by low levels of fibrinogen whereas increased levels is a strong independent factor for development of arterial thromboembolism. We compare PT derived method & clauss method of quantitative fibrinogen estimation in 2 groups of patients. Group 1:with Normal coagulation parameters and liver function tests and Group 2:With Deranged coagulation parameters &/or liver function tests. Materials & methods: Reagents for quantitative fibrinogen determination on human citrated plasma using IL coagulation system based on absorbance changes at 450 nm during clotting process of PT were used. Normal range of fibrinogen levels were determined from samples of 20 healthy subjects. Sample size of 64 patients is considered out of whom 15 are cases of solid malignancy, 45 of hematological malignancy (20 of which are APML) & 4 patients are on oral anticoagulants. They are segregated in 2 groups based on their coagulation parameters & LFT’s. Result: In patients with normal coagulation profile ie group 1, clauss method was not statistically significant (p value >0.05) whereas in patients with deranged coagulation profile ie group 2, clauss method was statistically significant (p value <0.05). Conclusion: Clauss method is preferred in oncology patients for quantitative fibrinogen estimation as compared to PT derived method.

**Introduction:**
Fibrinogen is a major plasma protein( normal conc. 1.5-4g/l which is synthesized in hepatocytes predominantly. It comprises each of 3 polypeptide chains (Aa, Bb & gamma) linked by disulphide bridges. Thrombin cleaves Aa & Bb chains to release fibrinopeptides A & B resulting in formation of fibrin monomers that polymerize to form insoluble fibrin clot (1). It is also an acute phase reactant(3) & can be raised in following conditions:

1. Physiological
   a) Increasing age
   b) Seasonal variation
   c) Pregnancy & OCP’s
   d) Post menopause
2. Inflammatory states
3. Disseminated malignancy

Clinical utility of fibrinogen assays:

1) For general haemostatic screening in combination of PTA/PTT
2) Investigation of haemorrhagic states (afibrinogenemia, hypofibrinogenemia) acquired or congenital dysfibrinogenemia
3) Investigation of unexpected coagulation tests
4) Risk assessment profiling of arterial diseases.

A variety of different fibrinogen assays have been used for various clinical indications such as :

1. Clauss assay
2. PT derived method
3. Clottable protein assay
4. Immunological assay
5. Gravimetric assays
6. Sulphite pptn. Tests

Our study aims to assess applicability of clauss & PT derived method in quantitative fibrinogen estimation.

**Materials/methods:**
Our study group comprises of 64 oncology patients.

**Figure 1: Pie chart showing patient breakup:**

- 15- solid malignancy
- 45- hematological malignancy: 25 APML, 20 non APML
- 4 – oral anticoagulants.

Total study group is further divided into 2 subgroups based on coagulation parameters:

Group 1 : with normal coagulation profile
Group 2 : with deranged coagulation profile

Normal range of fibrinogen determined from blood samples of normal healthy subjects : 200-450 mg/dl.

**Pre test variables:**

1. Anticoagulant : 3.2% tri sodium citrate
2. Correct filling: 9 parts blood to 1 part citrate
3. Haematocrict: adjust citrate for polycythemia
4. Venepuncture: clean, fast, minimal stasis
5. Blood & plasma inspection : clots, hemolysis, lipemia, icterus
6. Storage: 4 degree C for 48 hrs.(unless DIC)
Coagulation system used in our set up for fibrinogen estimation is ACL- elite pro of Internal laboratories (IL) which works on photo optical principle utilizing a filter of wavelength 405 nm.

**Principle:**

1. **Calibration curve**
   - Kit insert: Concentration used to test sample
   - Log of 3 serial plasma dilutions (preferably 5) & clotting time.
   - Fibrinogen C kit: Bovine thrombin reagent, with bovine albumin, calcium chloride, buffer & stabilizers.
   - Recombiplastin 2G kit: 1) lyophilised recombinant human tissue factor- reagent 2) diluents- calcium chloride, polybrene & preservative.

2. **ACL calculates fibrinogen value in mg/dl using a calibration curve which correlates fibrinogen conc. of 3 calibrations & their LS ratios.**

**Results:**

- **Group 1 - pts. TOTAL = 32**
  - With normal coagulation parameters
  - Figure 3: comparison between two methods in group I

- **Group 2 - pts. Total =32**
  - with deranged coagulation profile
  - Figure 4: comparison between two methods in group II

Both methods are compared in 2 groups & results are interpreted as chi square test. They are as follows:

1. **In patients with normal coagulation profile ie group 1**
   - Clauss method was not statistically significant at 95% confidence limit in comparison with PT derived method as p>0.05.
   - In patients with deranged coagulation profile ie group 2, clauss method was statistically significant at 95% confidence limit in comparison with PT derived method as p<0.05.

2. **Mean +/- S.D for Clauss method in group 1 is 318+/-106 & for group 2 patients is 239+/-97**

3. **Mean +/- S.D for PT derived method in group 1 is 580+/-297 & for group 2 patients is 496+/-330**

4. **Correlation between 2 methods in group 1 & group 2 patients was 0.77 & 0.78 which means that they show linear correlation.**

**In group 2 sample:**

Patients with increased PT & normal APTT - 19

- **CLAUSS**
  - low: 12
  - Normal: 4
  - high: 1

Patients with increased APTT & normal PT - 7

- **CLAUSS**
  - low: 4
  - Normal: 3
  - high: 0

Patients with increased PT & APTT - 6

- **CLAUSS**
  - low: 4
  - Normal: 1
  - high: 1

The recommended types of fibrinogen assays in different clinical situations affecting oncology patients:

- **Solid malignancies:** Clauss
- **APML:** Clauss
- **Non APML hematological malignancies:** Clauss
- **Patients on oral anticoagulants:** Clauss

**Discussion:**

Clauss method - merits & demerits:

- Suitable for detecting weak fibrin formation.
- Since it is a photooptical method, it is often affected by turbid & lipaemic samples or due to presence of bile or free haemoglobin.
- Potential for high carryover due to high conc. Of thrombin which may contaminate subsequent tests like PT APTT resulting in false shortening of clotting times.
- Selection of poor quality of standard plasma or calibrant may cause poor linearity in photo optical coagulometers & poor parallelism with serial dilutions of test plasma resulting in poor potency particularly for samples with low fibrinogen levels.

Clauss method – recommendations:

- Assays should not be performed within 4 hours of administration of unfractioned heparin or from heparin contaminated venous or arterial lines.
- Reagent should be checked for expiry or pH change.
- Quality control for reagants are mandatory to check for temporal drift.
Research Paper

- Reagent delivery system should be appropriately cleaned to avoid carry over.
- Calibration curve must be linear & should include at least 3 (but preferably 5) dilutions of plasma.
- Test samples must be rediluted if they are outside the linear range of assay.

PT derived method- merits & demerits:
- Used as a general haemostatic screening with PT & APTT in patients where normal fibrinogen values can be predicted such as epidemiological studies of normal populations.
- In thrombolytic therapy, FDP's interfere with claus assay but not in PT derived method.
- Determinants like method of calibration, type of analyser, reagent, optical clarity & nature of coagulopathy can affect quantitative fibrinogen estimation.
- Precision is inadequate in PT derived method if either PT was prolonged (e.g. As a result of anticoagulants) or fibrinogen levels were high.

Conclusion:
Claus method is standard diagnostic test for quantitative fibrinogen estimation. For routine use both methods are comparable and can be used in combination with PT & aPTT for general hemostatic screening.

REFERENCE
2. Chitole: type of thromboplastin reagent has important effects on the prothrombin time-derived fibrinogen potency: Laboratory haematology 4:149-155.